{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T11:14:22Z","timestamp":1785928462256,"version":"3.56.0"},"reference-count":41,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2012,1,24]],"date-time":"2012-01-24T00:00:00Z","timestamp":1327363200000},"content-version":"vor","delay-in-days":11030,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[1981,11,12]]},"abstract":"<jats:p>Biogenesis of tetrahydrofolate cofactors essential for bacterial growth and survival is blocked by sulfamethoxazole\u2010trimethoprim. An intravenous form of the antimicrobial combination has recently been approved for the treatment of acute, symptomatic, bacterial pyelonephritis, recurrent urinary tract infections, shigellosis, and <jats:italic>Pneumocystis carinii<\/jats:italic> pneumona. Intravenous sulfamethoxazole\u2010trimethoprim has emerged as an invaluable agent for the management of selected infections, including bacterial meningitis and Salmonella bacteremia, where limited therapeutic alternatives exist. In addition, co\u2010administration of intravenous sulfamethoxazole\u2010trimethoprim with a carboxypenicillin provides an empiric treatment for the infected granulocytopenic patient that compares favorably with standard combinations.<\/jats:p><jats:p>Adverse events unique to the intravenous form of the drug consist of phlebitis and fluid imbalances. Fluid overload results from the relatively large volumes of 5% dextrose solution required as diluent.<\/jats:p>","DOI":"10.1002\/j.1875-9114.1981.tb02542.x","type":"journal-article","created":{"date-parts":[[2015,12,16]],"date-time":"2015-12-16T09:58:43Z","timestamp":1450259923000},"page":"206-211","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Intravenous Sulfamethoxazole\u2010Trimethoprim: Pharmacokinetics, Therapeutic Indications, and Adverse Reactions"],"prefix":"10.1002","volume":"1","author":[{"given":"Richard","family":"Gleckman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson M.","family":"Gantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis W.","family":"Joubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,24]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"893","article-title":"Trimethoprim\u2010sulfamethoxazole","volume":"36","author":"Gleckman R","year":"1979","journal-title":"Am J Hosp Pharm"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.15.3.447"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.17.2.132"},{"key":"e_1_2_1_5_2","unstructured":"LewinEB.The pharmacokinetics of Bactrim Roche solution for intravenous infusion in high dosage. In: Proceedings of Tenth International Congress of Chemotherapy Zurich Switzerland.September 1823 1977."},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/5.6.717"},{"key":"e_1_2_1_7_2","first-page":"07110","volume-title":"Data on file","author":"Hoffman\u2010LaRoche Inc."},{"key":"e_1_2_1_8_2","first-page":"102","article-title":"The pharmacokinetic characteristics of sulfamethoxazole and trimethoprim after intravenous administration to normal subjects","volume":"9","author":"Gustafson JH","year":"1979","journal-title":"Acad Pharm Sci Abstracts"},{"key":"e_1_2_1_9_2","first-page":"691","volume-title":"Current chemotherapy and infectious disease","author":"Siber G","year":"1980"},{"key":"e_1_2_1_10_2","doi-asserted-by":"crossref","unstructured":"BernardN PozetN ZechPet al.Pharmacokinetics of Bactrim in renal insufficiency. In: Proceedings of International Congress on Pharmacology Paris.1978 Part 2.975.","DOI":"10.1016\/B978-0-08-023768-8.52513-5"},{"key":"e_1_2_1_11_2","first-page":"1004","article-title":"Stability of trimethoprim\u2010sulfamethoxazole injection in two infusion fluids","volume":"38","author":"Lesko L","year":"1981","journal-title":"Am J Hosp Pharm"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1978.tb131329.x"},{"key":"e_1_2_1_13_2","first-page":"250","volume-title":"Pneumocystis pneumonia","year":"1981"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(78)80028-6"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-198001000-00001"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-92-6-762"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(81)90830-5"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197609232951308"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1981.00340070106021"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(80)90217-X"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1981.00340070024006"},{"key":"e_1_2_1_22_2","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/jama.1976.03260380033022","article-title":"Trimethoprim\u2010sulfamethoxazole therapy for shigellosis","volume":"235","author":"Nelson JD","year":"1976","journal-title":"JAMA"},{"key":"e_1_2_1_23_2","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1542\/peds.59.5.726","article-title":"Trimethoprim\u2010sulfamethoxazole compared to ampicillin in the treatment of shigellosis","volume":"59","author":"Chang MJ","year":"1977","journal-title":"Pediatrics"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-198107000-00004"},{"key":"e_1_2_1_25_2","first-page":"484","article-title":"Some clinical and haematological features of typhoid fever in Zambia treated with co\u2010trimoxazole","volume":"53","author":"Obineche EN","year":"1976","journal-title":"East Afr Med J"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.1975.tb04376.x"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-84-1-50"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(79)80740-4"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.26.10.747"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.52.2.152"},{"key":"e_1_2_1_31_2","first-page":"2159","article-title":"Intravenous bactrim: a preliminary report","volume":"47","author":"Goodwin NM.","year":"1973","journal-title":"S Afr Med J"},{"key":"e_1_2_1_32_2","first-page":"91","article-title":"The intravenous infusion of co\u2010trimoxazole in cases of septicaemia: Tolerance and results of treatment","volume":"8","author":"Olc\u00e9n P","year":"1976","journal-title":"Scand J Infect Dis"},{"key":"e_1_2_1_33_2","first-page":"96","article-title":"Co\u2010trimoxazole in cases of gram\u2010negative septicaemia","volume":"8","author":"Franz\u00e9n C","year":"1976","journal-title":"Scand J Infect Dis"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.51.592.105"},{"key":"e_1_2_1_35_2","article-title":"Clinical experience with intravenous trimethoprim\u2010sulfamethoxazole for serious infections","author":"Schmidt U","journal-title":"Rev Infect Dis"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.3109\/inf.1975.7.issue-1.15"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1977.tb12517.x"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1979.tb11277.x"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.6135.462"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800670206"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-94-6-780"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.6131.172"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fj.1875-9114.1981.tb02542.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fj.1875-9114.1981.tb02542.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/j.1875-9114.1981.tb02542.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:15:42Z","timestamp":1761048942000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/j.1875-9114.1981.tb02542.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1981,11,12]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1981,11,12]]}},"alternative-id":["10.1002\/j.1875-9114.1981.tb02542.x"],"URL":"https:\/\/doi.org\/10.1002\/j.1875-9114.1981.tb02542.x","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[1981,11,12]]},"assertion":[{"value":"2012-01-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}